Hema.to

Hema.to is a Munich-based deep-tech AI company that develops cloud-based software for the early and accurate diagnosis of blood cancers and immune diseases through advanced cytometry analysis. Their AI-powered platform significantly reduces the time needed for blood sample analysis—from about 20 minutes to just one—while improving diagnostic accuracy for conditions like leukemia and lymphoma. Hema.to serves clinical laboratories and hematology specialists by automating and enhancing cytometry workflows, enabling personalized treatment based on each patient’s unique immune profile. The company has demonstrated strong growth momentum, having secured €3.6 million in funding and achieved CE-IVD and FDA registration, with its solutions already in routine use in leading European labs[1][2][3].

Founded in 2021 by Dr. Karsten Miermans and a team of data scientists and biomedical experts, Hema.to emerged from a collaboration with Europe’s largest leukemia lab, which sought to accelerate and improve internal cytometry workflows. The founders leveraged their combined expertise in biophysics, AI, and hematology to create a world-first AI prototype that addresses common manual workflow pain points in clinical cytometry. Early pivotal moments include successful clinical studies across multiple centers and adoption in routine clinical practice, validating the platform’s impact on diagnostic speed and accuracy[3][4].

Core Differentiators

• AI-driven automation: Hema.to’s platform automates cytometry data analysis, removing operator variability and ensuring expert-level reproducibility.
• Speed and efficiency: Cuts analysis and reporting time by over 80%, enabling urgent cases to be prioritized instantly.
• Regulatory compliance and security: CE-IVD certified, FDA registered, GDPR-compliant with encrypted, EU-hosted data privacy.
• Flexible, cloud-based workflows: Panel-independent, allowing remote access and real-time collaboration among clinical teams.
• Multidisciplinary team: Combines expertise in AI, biophysics, hematology, software engineering, and clinical research to continuously innovate[2][3][4].

Role in the Broader Tech Landscape

Hema.to rides the growing trend of applying AI and machine learning to healthcare diagnostics, particularly in precision medicine and immunology. The timing is critical as clinical labs face increasing workloads and staff shortages, creating demand for faster, more reliable diagnostic tools. By improving cytometry workflows, Hema.to addresses a global market worth several billion dollars and contributes to advancing personalized treatment strategies for blood cancers. Its cloud-based, scalable solution also aligns with broader healthcare digitization and data-driven medicine trends, influencing how clinical labs operate and collaborate internationally[1][3].

Quick Take & Future Outlook

Looking ahead, Hema.to is positioned to expand its clinical footprint by growing its team of AI engineers, immunologists, and business developers to enhance product capabilities and market reach. Trends such as increasing adoption of AI in diagnostics, regulatory acceptance of AI tools, and the push for personalized medicine will shape its trajectory. The company’s influence is likely to grow as it helps standardize and automate cytometry analysis globally, potentially becoming a key enabler of faster, more accurate blood cancer diagnosis and treatment personalization. This aligns with its mission to save lives by making clinical analysis objective, reproducible, and accessible[1][3][4].